CJC-1295 DAC vs No DAC: Comparing Two GHRH Analog Research Formats
Among the most widely used research peptides in growth hormone-releasing hormone (GHRH) pathway investigation, CJC-1295 occupies a central position. What makes this compound particularly interesting from a research design perspective is that it is available in two distinct formats: CJC-1295 with DAC and CJC-1295 without DAC (Mod GRF 1-29). These two formats exhibit fundamentally different pharmacokinetic profiles in preclinical models, making the choice between them a meaningful variable in research protocol design.
This comparative analysis examines the structural differences, the DAC technology itself, and the practical implications for researchers selecting between these two GHRH analog formats.
The Foundation: Modified GRF 1-29
Both CJC-1295 formats share a common peptide core derived from the first 29 amino acids of growth hormone-releasing hormone (GRF 1-29, also known as sermorelin). The native GRF 1-29 sequence, while biologically active at the GHRH receptor, is rapidly degraded in biological systems, primarily by dipeptidyl peptidase IV (DPP-IV) cleavage at position 2.
To address this instability, researchers at ConjuChem Biotechnologies developed a modified version incorporating four amino acid substitutions designed to resist enzymatic degradation (Jette et al., 2005). These substitutions are:
- Ala2 replaced with D-Ala2: Directly blocks the DPP-IV cleavage site through stereochemical inversion
- Gln8 replaced with Asn8: Improves stability against asparagine deamidation
- Ala15 replaced with Ala15 (with Leu substitution at other positions): Additional stabilization of the peptide backbone
- Met27 replaced with Leu27: Eliminates the oxidation-prone methionine residue
This modified core sequence, known as Mod GRF 1-29 or CJC-1295 without DAC, retains full binding affinity for the GHRH receptor while exhibiting substantially improved resistance to enzymatic degradation compared to native GRF 1-29.
Drug Affinity Complex (DAC) Technology
The DAC format represents an additional layer of modification beyond the sequence substitutions. Jette et al. (2005) described the Drug Affinity Complex as a bioconjugation strategy designed to extend peptide persistence in biological systems through reversible binding to endogenous serum albumin.
The Maleimidopropionic Acid Linker
The DAC system utilizes a maleimidopropionic acid (MPA) reactive group attached to a lysine residue on the modified GRF 1-29 peptide. The key features of this technology include:
- Reactive maleimide group: Forms a covalent thioether bond with the free sulfhydryl group on Cysteine-34 of serum albumin
- Spacer element: A short linker provides physical separation between the peptide and the albumin binding site, preserving receptor interaction capability
- In situ conjugation: The binding occurs after the peptide enters the biological system, distinguishing this approach from pre-formed albumin conjugates
Albumin Binding and Extended Persistence
Once bound to albumin, the CJC-1295 DAC conjugate benefits from albumin’s inherently long circulation time in biological systems. Alba et al. (2006) reported that the albumin-bound form demonstrated markedly extended pharmacokinetic profiles in preclinical models compared to the unconjugated peptide, with measurable concentrations persisting for days rather than minutes.
The binding to albumin also confers additional stability advantages:
- Steric protection: The large albumin molecule shields the peptide from proteolytic enzymes
- Reduced renal clearance: The albumin-peptide complex exceeds the kidney filtration threshold
- Reservoir effect: Albumin-bound peptide serves as a sustained-release depot in the circulatory system
Pharmacokinetic Differences in Preclinical Models
The pharmacokinetic distinction between the two formats is the primary factor guiding research compound selection. Data from preclinical studies reveal markedly different temporal profiles.
CJC-1295 No DAC (Mod GRF 1-29)
CJC-1295 without DAC exhibits a pharmacokinetic profile characterized by:
- Rapid onset: Peak activity observed within minutes of administration in preclinical models
- Shorter duration: Effective research window of approximately 30 minutes to several hours, depending on the model system
- Pulsatile signaling pattern: The relatively brief activity period produces discrete, pulse-like stimulation of the GHRH receptor
- Multiple administration protocols: Research designs often employ repeated administration to achieve sustained pathway activation
CJC-1295 with DAC
CJC-1295 DAC demonstrates a fundamentally different profile:
- Extended duration: Teichman et al. (2006) reported prolonged pharmacokinetic profiles in preclinical models, with measurable activity persisting well beyond the no-DAC format
- Sustained elevation: Rather than discrete pulses, the DAC format produces a more continuous pattern of GHRH receptor activation
- Reduced administration frequency: The extended persistence allows less frequent administration in research protocols
- Gradual onset: Time to peak effect is longer compared to the no-DAC format due to the albumin conjugation kinetics
Research Design Implications
The choice between DAC and no-DAC formats is not a question of which is “better” but rather which is more appropriate for the specific research question being investigated. Each format offers distinct advantages for different study types.
When No-DAC Format May Be Preferred
- Studies examining pulsatile signaling: The shorter action profile of Mod GRF 1-29 more closely mimics the natural pulsatile pattern of endogenous GHRH release
- Acute response studies: When researchers need to measure immediate downstream effects of GHRH receptor activation
- Combination research protocols: When CJC-1295 is being studied alongside other compounds such as Ipamorelin or other growth hormone secretagogues, the pulsatile format allows more precise temporal control
- Mechanistic studies: When the goal is to understand receptor-level signaling events within defined time windows
When DAC Format May Be Preferred
- Extended observation studies: When research protocols span multiple days and consistent GHRH pathway activation is desired
- Pharmacokinetic research: Studies specifically examining the DAC technology as an albumin-binding model system
- Reduced-handling protocols: When minimizing the number of compound administrations is experimentally advantageous
- Sustained pathway activation studies: When continuous rather than pulsatile GHRH receptor engagement is the intended experimental condition
Practical Laboratory Considerations
Beyond pharmacokinetic profiles, several practical factors distinguish the two formats in laboratory use:
- Reconstitution: Both formats are typically supplied as lyophilized powders and reconstituted in bacteriostatic water for research use
- Storage stability: Both formats should be stored lyophilized at -20 degrees Celsius; reconstituted solutions should be refrigerated
- Molecular weight: The DAC modification adds approximately 300 Da to the molecular weight, which may be relevant for mass spectrometry-based quantification
- Maleimide reactivity: The DAC format contains a reactive maleimide group; researchers should be aware of potential non-specific reactions with thiol-containing compounds in experimental buffers
Ionescu and Bhatt (2005) noted that understanding the conjugation chemistry is particularly important when designing assays to distinguish between free and albumin-bound forms of the DAC conjugate in biological samples.
Summary for Researchers
The availability of CJC-1295 in both DAC and no-DAC formats provides researchers with flexibility to match compound pharmacokinetics to their specific experimental requirements. The DAC format offers extended persistence through albumin binding, while the no-DAC format (Mod GRF 1-29) provides a shorter, more pulsatile activity profile. Neither format is inherently superior; the appropriate selection depends entirely on the research question, model system, and experimental design under consideration.
Both formats are available for research purposes at Aureum Peptides.
References
- Alba, M., Fintini, D., Saggioro, S., Walsh, C.P., Bhatt, R.S., Hattersley, A.T., & Bhatt, D.K. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290-E1294.
- Ionescu, M. & Bhatt, D.K. (2005). Development of immunoassays for CJC-1295, a long-acting GHRH analog. Proceedings of the Endocrine Society Annual Meeting.
- Jette, L., Leger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Bhatt, D.K., & Bhatt, R.S. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats. Endocrinology, 146(7), 3052-3058.
- Teichman, S.L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J.P., & Bhatt, R.S. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805.
Disclaimer: All products sold by Aureum Peptides are intended for laboratory and research use only. Not for human consumption. CJC-1295 (with and without DAC) is sold as a research chemical. No statements on this page have been evaluated by the FDA. This product is not intended to diagnose, treat, supports research into, or may modulate any disease. For Research Use Only.
